Equities

Adicon Holdings Ltd

Adicon Holdings Ltd

Actions
Health CareMedical Equipment and Services
  • Price (HKD)9.27
  • Today's Change0.17 / 1.87%
  • Shares traded146.00k
  • 1 Year change-25.96%
  • Beta--
Data delayed at least 15 minutes, as of Jul 26 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Adicon Holdings Ltd is an investment holding company principally engaged in the provision of independent clinical laboratory (ICL) services. The Company primarily provides testing services to hospitals, medical institutions, medical examination centers, consumers, pharmaceutical companies and contract research organizations (CROs). The Company's inspection services mainly include routine tests, esoteric tests, clinical immunologic testing, clinical chemistry testing, clinical molecular biology testing, pathology testing and others testing. The Company is also engaged in the sales of medical testing equipment. The Company principally conducts its businesses in the domestic market.

  • Revenue in HKD (TTM)3.56bn
  • Net income in HKD253.58m
  • Incorporated2008
  • Employees5.71k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
EuroEyes International Eye Clinic Ltd714.29m131.24m1.66bn290.0012.661.477.552.330.3950.3952.153.410.433623.28114.792,463,066.008.096.189.197.2046.9745.8118.6614.314.53--0.248--17.0412.4446.6929.9134.24--
Town Health International Medical Gp Ltd1.83bn-194.21m1.79bn1.40k--0.5536--0.9792-0.0287-0.02870.27060.47870.396324.255.041,310,249.00-3.44-1.21-4.29-1.4427.3829.06-8.68-4.013.161.340.1121--19.3710.32-1,370.26---25.95-13.65
Rici Healthcare Holdings Ltd3.23bn392.75m1.91bn9.41k4.861.572.820.59070.2470.2472.030.7650.650345.8010.35343,230.608.733.2416.255.7841.7537.0013.435.930.64715.640.67050.0026.0116.8556.06--2.51--
Chaoju Eye Care Holdings Ltd1.48bn247.13m2.10bn2.60k8.380.80145.661.420.35450.35452.133.710.485114.4626.75569,303.807.828.088.809.5645.3543.8116.1215.474.9025.560.077951.5738.3316.7021.9242.68-2.33--
Arrail Group Ltd1.88bn18.53m2.26bn3.46k103.441.227.681.200.03870.03873.973.270.552924.999.55544,082.300.4249-14.220.5856-67.5422.4919.470.7685-24.541.984.470.3643--18.4610.08107.80------
Mega Genomics Ltd163.34m32.43m2.26bn229.0066.272.9046.4413.860.14460.14460.75243.300.201415.921.01713,273.204.00--4.60--58.36--19.85--5.80--0.07--3.82--270.50------
C-Mer Medical Holdings Ltd1.92bn62.00m3.20bn3.27k51.631.7210.431.660.04940.04941.531.480.68128.9338.29587,828.903.060.92373.871.1232.1729.954.491.441.7516.840.15445.3311.0934.98383.427.8128.01--
China Resources Medical Holdings Com Ltd10.91bn278.18m4.08bn20.17k14.320.6514.030.37430.220.228.634.840.642324.506.63540,937.702.083.243.494.8018.8620.293.246.600.600523.910.247927.9527.9237.46-3.07-9.7753.23-10.66
Yunkang Group Ltd962.44m-110.40m5.51bn1.51k--2.42--5.73-0.1854-0.18541.573.670.188919.070.4519637,377.70-2.166.70-3.8811.1936.5442.42-11.4310.991.75--0.39619.89-76.278.38-127.10--33.22--
Jinxin Fertility Group Ltd3.01bn372.15m6.62bn3.27k18.140.59949.682.200.13230.13231.104.000.185125.8221.31919,900.702.302.642.723.0142.1541.7612.4414.900.757511.580.214741.5217.9524.78184.6015.6552.59--
Jiangxi Rimag Group Co Ltd-100.00bn-100.00bn6.70bn1.01k------------------------------------------------18.42--12,101.92------
Adicon Holdings Ltd3.56bn253.58m6.73bn5.71k27.593.6614.501.890.3360.3364.972.54------623,183.90--------43.49--7.95--1.786.600.3734---32.15---65.50------
Gushengtang Holdings Ltd2.51bn272.27m8.82bn2.66k32.713.5821.903.521.111.1110.2710.090.774812.5917.25943,298.008.43-4.8710.69-9.9130.1337.0910.89-6.672.38--0.1385--43.0126.1839.45--26.99--
Data as of Jul 26 2024. Currency figures normalised to Adicon Holdings Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

2.42%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 04 Jul 202412.04m1.66%
Grandeur Peak Global Advisors LLCas of 30 Apr 20244.28m0.59%
E Fund Asset Management Co. Ltd.as of 31 Dec 2023486.50k0.07%
Penghua Fund Management Co., Ltd.as of 31 Dec 2023309.00k0.04%
Yinhua Fund Management Co., Ltd.as of 31 Dec 2023114.50k0.02%
BlackRock Fund Advisorsas of 04 Jul 2024110.00k0.02%
TIAA-CREF Investment Management LLCas of 31 May 2024102.50k0.01%
Ping An Fund Management Co., Ltd.as of 31 Dec 202368.00k0.01%
BlackRock Advisors (UK) Ltd.as of 04 Jul 202463.00k0.01%
State Street Global Advisors Ltd.as of 04 Jul 202429.00k0.00%
More ▼
Data from 31 Dec 2023 - 18 Jul 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.